Befejeződött1. fázis
A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy
Key facts
- Where
- Helsinki, FinnországSee the site
- Phase
- 1. fázis
Where in Finnország
- Docrates OyHelsinki, FinnországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- TILT Biotherapeutics Oy
- Trial code
- EU 2024-518088-37-01
- Record updated
- 2025. december 10.